These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 29980598)
1. Identification of two distinct peptide-binding pockets in the SH3 domain of human mixed-lineage kinase 3. Kokoszka ME; Kall SL; Khosla S; McGinnis JE; Lavie A; Kay BK J Biol Chem; 2018 Aug; 293(35):13553-13565. PubMed ID: 29980598 [TBL] [Abstract][Full Text] [Related]
2. Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain. Zhang H; Gallo KA J Biol Chem; 2001 Dec; 276(49):45598-603. PubMed ID: 11590155 [TBL] [Abstract][Full Text] [Related]
3. Solution NMR structure and ligand identification of human Gas7 SH3 domain reveal a typical SH3 fold but a non-canonical ligand-binding mode. Nie Y; Zhu J; Ramelot TA; Kennedy MA; Liu M; He T; Yang Y Biochem Biophys Res Commun; 2019 Sep; 516(4):1190-1195. PubMed ID: 31296381 [TBL] [Abstract][Full Text] [Related]
4. Why the first self-binding peptide of human Zhou P; Yan F; Miao Q; Chen Z; Wang H J Biomol Struct Dyn; 2021 Jan; 39(1):310-318. PubMed ID: 31872783 [TBL] [Abstract][Full Text] [Related]
5. Phage display selection of ligand residues important for Src homology 3 domain binding specificity. Rickles RJ; Botfield MC; Zhou XM; Henry PA; Brugge JS; Zoller MJ Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10909-13. PubMed ID: 7479908 [TBL] [Abstract][Full Text] [Related]
7. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands. Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059 [TBL] [Abstract][Full Text] [Related]
8. Directed discovery of bivalent peptide ligands to an SH3 domain. Ferguson MR; Fan X; Mukherjee M; Luo J; Khan R; Ferreon JC; Hilser VJ; Shope RE; Fox RO Protein Sci; 2004 Mar; 13(3):626-32. PubMed ID: 14978303 [TBL] [Abstract][Full Text] [Related]
9. Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2. Sparks AB; Rider JE; Hoffman NG; Fowlkes DM; Quillam LA; Kay BK Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1540-4. PubMed ID: 8643668 [TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions. Pisabarro MT; Serrano L; Wilmanns M J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566 [TBL] [Abstract][Full Text] [Related]
12. Why ligand cross-reactivity is high within peptide recognition domain families? A case study on human c-Src SH3 domain. He P; Wu W; Wang HD; Liao KL; Zhang W; Lv FL; Yang K J Theor Biol; 2014 Jan; 340():30-7. PubMed ID: 24021866 [TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. Alvarado JJ; Betts L; Moroco JA; Smithgall TE; Yeh JI J Biol Chem; 2010 Nov; 285(46):35455-61. PubMed ID: 20810664 [TBL] [Abstract][Full Text] [Related]
14. Solution structure and peptide binding of the SH3 domain from human Fyn. Morton CJ; Pugh DJ; Brown EL; Kahmann JD; Renzoni DA; Campbell ID Structure; 1996 Jun; 4(6):705-14. PubMed ID: 8805554 [TBL] [Abstract][Full Text] [Related]
15. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Arold S; Franken P; Strub MP; Hoh F; Benichou S; Benarous R; Dumas C Structure; 1997 Oct; 5(10):1361-72. PubMed ID: 9351809 [TBL] [Abstract][Full Text] [Related]
16. Complete nucleotide sequence, expression, and chromosomal localisation of human mixed-lineage kinase 2. Dorow DS; Devereux L; Tu GF; Price G; Nicholl JK; Sutherland GR; Simpson RJ Eur J Biochem; 1995 Dec; 234(2):492-500. PubMed ID: 8536694 [TBL] [Abstract][Full Text] [Related]
17. Targeting the SH3 domain of human osteoclast-stimulating factor with rationally designed peptoid inhibitors. Han S; Liu Q; Wang F; Yuan Z J Pept Sci; 2016 Aug; 22(8):533-9. PubMed ID: 27443979 [TBL] [Abstract][Full Text] [Related]
18. Integrated in silico-in vitro characterization, identification and disruption of the intermolecular interaction between SH3 domain-containing protein kinases and human pituitary tumor-transforming gene 1. Li Y; Li M; Min W; Han G; Wang L; Chen C; Li Z; Zhang Y; Li J; Yue Z Gen Physiol Biophys; 2017 Jan; 36(1):91-98. PubMed ID: 27787230 [TBL] [Abstract][Full Text] [Related]
19. Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2. Rasmussen RK; Ji H; Eddes JS; Moritz RL; Reid GE; Simpson RJ; Dorow DS Electrophoresis; 1997; 18(3-4):588-98. PubMed ID: 9150946 [TBL] [Abstract][Full Text] [Related]
20. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Feng S; Chen JK; Yu H; Simon JA; Schreiber SL Science; 1994 Nov; 266(5188):1241-7. PubMed ID: 7526465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]